| 摘要 |
The present invention provides novel methods of inhibiting or preventing epithelial-mesenchymal transition (EMT) or endothelial-mesenchymal transition (EnMT), such as EMT or EnMT, associated with fibrosis and chronic tissue rejection. The present invention also provides methods for diagnosing or assessing whether a subject has or is at risk of developing a disease associated with CDH11 expression, as well as methods for determining the prognosis of a subject diagnosed with a CDH11-associated condition. The invention employs CDH11 antagonists to downmodulate CDH11 activity, thereby inhibiting EMT or EnMT.
|
